← All trials
NCT04976387
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 2, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Jul 26, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 200
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Loma Linda UniversityLead sponsor
- Loma Linda UniversityReponsible party - principal investigator
- Loma Linda UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.